Next Day Disclosure Returns - [Share Buyback]

Ascletis Pharma Inc. operates as a biotechnology company. The Company develops and discovers anti-viral drugs to address unmet medical needs in anti-viral, cancer, and fatty liver disease. Ascletis Pharma offers its services worldwide.

Next Day Disclosure Return

Announcements and Notices - [Other - Business Update]

Voluntary Announcement - Ascletis Announces Asc47, A Muscle-Preserving
Weight Loss Drug Candidate For Treatment Of
Obesity, In Combination With Semaglutide,
Demonstrated Superior Weight Loss To Semaglutide
Monotherapy In A Preclinical Model

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Next Day Disclosure Return

Next Day Disclosure Return

Voluntary Announcement - Ascletis Announces Asc47, A Muscle-Preserving Weight Loss Drug Candidate For Treatment Of Obesity, In Combination With Semaglutide, Demonstrated Superior Weight Loss To Semaglutide Monotherapy In A Preclinical Model

Next Day Disclosure Return

Next Day Disclosure Return